301: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 1

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?
In this episode, David Brühlmann welcomes Lena Tholen and Lars Stöckl of FyoniBio GmbH—two scientists who’ve dedicated their careers to optimizing cell line and process development for biopharma clients.
Topics covered in this episode:
• The trend toward outsourcing CMC development and the reasons behind it for both large pharma and small biotechs (07:27)
• How specialized CDMOs innovate and continuously improve cell line development platforms, giving clients access to new options and efficiencies (10:36)
• Real-world experience navigating project pitfalls from discovery to clinical studies—including differences between cell lines and processes (13:38)
• The importance of retaining key activity assays and critical knowledge in-house—and the risks of over-reliance on consultants (15:04)
• Key factors that help biotech companies thrive when partnering with CDMOs, including internal expertise, flexibility, and milestone planning (17:32)
Smart insight: Product quality and success are designed in early through careful choices about cell lines, processes, and analytical strategies. Streamlined outsourcing and platform innovation can turbocharge development, but only when matched with committed, knowledgeable in-house leadership and measured, forward-thinking investment. The next time a CMC decision seems minor or a shortcut tempting, remember the long game—your product quality, speed to clinic, and future cost may all depend on it.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
• Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
• Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
• Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
• Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
Website: fyonibio.com
LinkedIn:linkedin.com/in/dr-lars-stoeckl
LinkedIn: linkedin.com/in/lena-tholen-80642a11a
Support the show (buzzsprout.com/2263581/support)